Lv1
20 积分 2022-08-30 加入
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial
1天前
待确认
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial
1天前
已完结
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer
15天前
已完结
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
16天前
已关闭
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
16天前
已完结
Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
19天前
已完结
乳腺癌中紫杉类药物临床应用专家共识
22天前
已完结
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study
26天前
已完结
Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial
27天前
已关闭
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
27天前
已关闭
皖公网安备34019202002308
